AI Terminal
GRAFT POLYMER (UK) PLC
Declaration of Voting Results & Voting Rights Announcements • Jul 31, 2025
5092_dva_2025-07-31_ffbf2a0e-9c45-4d00-b16e-7bcbb3c2af44.html
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2497T
Solvonis Therapeutics PLC
31 July 2025
31 July 2025
Solvonis Therapeutics plc
("Solvonis" or the "Company")
Total Voting Rights
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, confirms that the Company's issued share capital as at the date of this announcement comprises 6,262,104,024 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 6,262,104,024.
The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.
Enquiries:
| Solvonis Therapeutics plc | [email protected] |
| Anthony Tennyson, CEO & Executive Director | |
| Allenby Capital Limited (Financial Adviser and Joint Broker) | +44 (0) 20 3328 5656 |
| Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance) Guy McDougall (Sales & Corporate Broking) |
|
| Singer Capital Markets (Joint Broker) | +44(0) 20 7496 3000 |
| Phil Davies |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TVREALXEDDFSEFA